Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque‐type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Eur Acad Dermatol Venereol
Main Authors: Gerdes, S., Thaçi, D., Griffiths, C.E.M., Arenberger, P., Poetzl, J., Wuerth, G., Afonso, M., Woehling, H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles and Short Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887937/
https://ncbi.nlm.nih.gov/pubmed/28960486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14605
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados